检索结果-南通市图书馆

Inflammatory bowel disease in Tuzla Canton,Bosnia-Herzegovina:A prospective 10-year follow-up

World Journal of Gastroenterology 2021年第20期27卷 2630-2642页

作者： Emir Tulumović Nermin Salkić Denijal Tulumović Department of Gastroenterology and Hepatology University Clinical Center TuzlaTuzla 75000Tuzlanski KantonBosnia and Herzegovina Department of Nephrology Dialysis and TransplantationUniversity Clinical Center TuzlaTuzla 75000Tuzlanski KantonBosnia and Herzegovina

BACKGROUND The incidence and prevalence of inflammatory bowel disease(IBD)vary between regions but have risen globally in recent decades.A lack of data from developing nations limits the understanding of IBD *** To perform a follow-up review of IBD epidemiology in the Tuzla Canton of Bosnia-Herzegovina during a 10-year period(2009-2019).METHODS We prospectively evaluated the hospital records of both IBD inpatients and outpatients residing in Tuzla Canton for the specified period of time between January 1,2009 and December 31,*** all our patients had undergone proximal and distal endoscopic evaluations at the hospital endoscopy unit,we used the hospital’s database as a primary data source,alongside an additional cross-relational search of the *** adult and pediatric patients were included in the *** were grouped by IBD type,phenotype,age,and *** rates were calculated with age standardization using the European standard *** in incidence and prevalence were evaluated as a 3-year moving average and average annual percentage change *** During the 10-year follow-up period,651 patients diagnosed with IBD were monitored(of whom 334,or 51.3%,were males,and 317,or 48.7%,were females).Of all the patients,346(53.1%)had been diagnosed with ulcerative colitis(UC),292(44.9%)with Crohn’s disease(CD),and 13(2%)with indeterminate colitis(IC).We observed 440 newly diagnosed patients with IBD:240(54.5%)with UC,190(43.2%)with CD,and 10(2.3%)with *** mean annual crude incidence rates were found to be 9.01/100000 population for IBD[95%confidence interval(CI):8.17-9.85],with 4.91/100000(95%CI:4.29-5.54)for UC and 3.89/100000(95%CI:3.34-4.44)for *** IBD prevalence in 2019 was 146.64/100000(95%CI:128.09-165.19),with 77.94/100000(95%CI:68.08-87.70)for UC and 65.77/100000(95%CI:54.45-74.1)for *** average annual IBD percentage change was 0.79%(95%CI:0.60-0.88),with-2.82%(95%CI:-2.67 to-2.97)for UC and

关键词： Inflammatory bowel disease Crohn's disease Ulcerative colitis indeterminate colitis Epidemiology Endoscopy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease

引用

World Journal of Gastrointestinal Pharmacology and Therapeutics 2016年第1期7卷 41-50页

作者： Anet A Soubières Andrew Poullis Department of Gastro- enterology St George’s Hospital University of London

There is currently no gold standard test for the diagnosis of inflammatory bowel disease (IBD). Physicians must rely on a number of diagnostic tools including clinical and endoscopic evaluation as well as histologic, serologic and radiologic assessment. The real difficulty for physicians in both primary and secondary care is differentiating between patients suffering from functional symptoms and those with true underlying IBD. Alongside this, there is always concern regarding the possibility of a missed, or delayed diagnosis of ulcerative colitis (UC) or Crohn’s disease. Even once the diagnosis of IBD has been made, there is often uncertainty in distinguishing between cases of UC or Crohn’s. As a consequence, in cases of incorrect diagnosis, optimal treatment and management may be adversely affected. Endoscopic evaluation can be uncomfortable and inconvenient for patients. It carries significant risks including perforation and in terms of monetary cost, is expensive. The use of biomarkers to help in the diagnosis and differentiation of IBD has been increasing over time. However, there is not yet one biomarker, which is sensitive of specific enough to be used alone in diagnosing IBD. Current serum testing includes C-reactive protein and erythrocyte sedimentation rate, which are cheap, reliable but non-specific and thus not ideal. Stool based testing such as faecal calprotectin is a much more specific tool and is currently in widespread clinical use. Non-invasive sampling is of the greatest clinical value and with the recent advances in metabolomics, genetics and proteomics, there are now more tools available to develop sensitive and specific biomarkers to diagnose and differentiate between IBD. Many of these new advances are only in early stages of development but show great promise for future clinical use.

关键词： Biomarkers Inflammatory bowel disease Ulcerative colitis Crohn&rsquo s disease indeterminate colitis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：